Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 1 35 versus TRI LO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 1 35 versus TRI LO LINYAH.
CYCLAFEM 1/35 vs TRI-LO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
None Documented
None Documented
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive